title: Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases.
abstract: The use of radiotherapy (RT) with chemotherapy has improved disease free survival and control in primary central nervous system lymphoma (PCNSL). We have encountered three patients with histologically documented central nervous system lymphoma. In all patients pathological diagnosis was B-cell lymphoma. We modified IDARAM regimen to R-IDARAM to enhance and optimize chemotherapeutic components for the treatment of PCNSL. We made three changes: (i) we added rituximab 375 mg/m(2) day 1; (ii) increased dose of MTX from 2 to 3 g/m(2); and (iii) administered two additional courses of R-IDARAM after cranial RT. Following complete staging after course 2, radiotherapy was applied at a dosage of 3600-4140 cGy in conventional schedule (180 or 200 cGy per day) to whole brain (with 3600 cGy to eyes in one case because of eye involvement) and then 2 additional courses of R-IDARAM (totally four courses) chemotherapy regimen were applied. Complete remission (CR) was achieved after first two cycles of R-IDARAM in patient 1 and 3 and after four cycles in patient 2. Currently, three patients have been alive for 29, 10, 15 months respectively. Currently there is no standard treatment modality for PCNSL. Increased dosage of MTX, adding rituximab and consolidation of the IDARAM to R-IDARAM regimen may improve disease control and outcome in PCNSL patients.
authors.affiliation: Department of Hematology, Gaziantep University Medical School, Gaziantep, Turkey. mmyilmaz@gantep.edu.tr
authors.forename: Mehmet
authors.initials: M
authors.lastname: Yilmaz
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Erkutlu
authors.forename: Sevil
authors.initials: S
authors.lastname: Kilciksiz
authors.forename: Mustafa
authors.initials: M
authors.lastname: Pehlivan
authors.forename: Vahap
authors.initials: V
authors.lastname: Okan
authors.forename: Mehmet
authors.initials: M
authors.lastname: Alptekin
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Sari
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000628:therapy*; D016371:Cranial Irradiation; D003561:Cytarabine / Q000627:therapeutic use; D003907:Dexamethasone; D006801:Humans; D015255:Idarubicin; D007150:Immunohistochemistry; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged
chemical_list: D003561:Cytarabine; D003907:Dexamethasone; D015255:Idarubicin